Proteomics

Dataset Information

0

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas - targeted data


ABSTRACT: Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes the peptide MHC (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1000 copies-per-cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting 4 epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Melanocyte, Skin

SUBMITTER: Lauren Stopfer  

LAB HEAD: Forest White

PROVIDER: PXD029884 | Pride | 2023-03-11

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
A375_100nM_1_Targeted.raw Raw
A375_100nM_3_Targeted.raw Raw
A375_100nm_2_Targeted.raw Raw
A375_1uM_1_Targeted.raw Raw
A375_1uM_2_Targeted.raw Raw
Items per page:
1 - 5 of 30
altmetric image

Publications

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.

Stopfer Lauren E LE   Rettko Nicholas J NJ   Leddy Owen O   Mesfin Joshua M JM   Brown Eric E   Winski Shannon S   Bryson Bryan B   Wells James A JA   White Forest M FM  

Proceedings of the National Academy of Sciences of the United States of America 20221201 49


Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma-namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies-may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition (MEKi) alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile chang  ...[more]

Similar Datasets

2022-11-15 | GSE185284 | GEO
2023-03-11 | PXD029860 | Pride
2024-06-22 | PXD050614 | Pride
2024-05-23 | PXD045346 | Pride
2019-05-17 | GSE127886 | GEO
2024-04-22 | GSE264527 | GEO
2024-04-23 | GSE255541 | GEO
2014-03-06 | E-GEOD-55624 | biostudies-arrayexpress
2023-11-14 | GSE245262 | GEO
2018-04-18 | GSE110948 | GEO